{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:27:43Z","timestamp":1791829663720,"version":"4.3.4"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1001\/jamadermatol.2020.3617","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T11:19:11Z","timestamp":1602674351000},"page":"1344","source":"Crossref","is-referenced-by-count":54,"title":["Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis"],"prefix":"10.1001","volume":"156","author":[{"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[{"name":"University Medical Center Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Lambert","sequence":"additional","affiliation":[{"name":"Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Zema","sequence":"additional","affiliation":[{"name":"Formerly AbbVie Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H. Z.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Formerly AbbVie Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Q.","family":"Wu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Garcia-Horton","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqian","family":"Geng","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin M.","family":"Valdes","sequence":"additional","affiliation":[{"name":"Formerly AbbVie Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avani","family":"Joshi","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"doi200056r1","doi-asserted-by":"publisher","first-page":"871-881.e871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi200056r2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence.","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi200056r3","doi-asserted-by":"publisher","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","article-title":"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis.","volume":"34","author":"Chandran","year":"2010","journal-title":"J Autoimmun"},{"issue":"6","key":"doi200056r4","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/bjd.2005.153.issue-6","article-title":"Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.","volume":"153","author":"Krueger","year":"2005","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi200056r5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","article-title":"Quality of life in patients with psoriasis: a systematic literature review.","volume":"9","author":"de Korte","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"2","key":"doi200056r6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000090652","article-title":"An Italian study on psoriasis and depression.","volume":"212","author":"Esposito","year":"2006","journal-title":"Dermatology"},{"issue":"3 Pt 1","key":"doi200056r7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases.","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi200056r8","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/S0190-9622(03)01136-8","article-title":"Quality of life issues in psoriasis.","volume":"49","author":"Choi","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"doi200056r9","first-page":"167","article-title":"A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values.","volume":"6","author":"M\u00f8ller","year":"2015","journal-title":"Patient Relat Outcome Meas"},{"issue":"6","key":"doi200056r10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","article-title":"Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate to severe  psoriasis: a randomized controlled trial.","volume":"154","author":"Reich","year":"2006","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi200056r11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000237871","article-title":"Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate to severe  plaque psoriasis.","volume":"219","author":"Reich","year":"2009","journal-title":"Dermatology"},{"issue":"6","key":"doi200056r12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/09546630701646172","article-title":"Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.","volume":"18","author":"Revicki","year":"2007","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"doi200056r13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi200056r14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials.","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"10148","key":"doi200056r15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate to severe  plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"doi200056r18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41687-017-0004-7","article-title":"The content validity of the PSS in patients with plaque psoriasis.","volume":"1","author":"Rentz","year":"2017","journal-title":"J Patient Rep Outcomes"},{"issue":"5","key":"doi200056r19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/00015550510032832","article-title":"Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis.","volume":"85","author":"Mazzotti","year":"2005","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"doi200056r21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/acp.1983.67.issue-6","article-title":"The hospital anxiety and depression scale.","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"doi200056r23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1477-7525-4-71","article-title":"The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.","volume":"4","author":"Shikiar","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"doi200056r24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.v27.1","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England.","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ"},{"issue":"2","key":"doi200056r25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","article-title":"The validity of the Hospital Anxiety and Depression Scale. An updated literature review.","volume":"52","author":"Bjelland","year":"2002","journal-title":"J Psychosom Res"},{"issue":"1","key":"doi200056r26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data.","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"issue":"6","key":"doi200056r27","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s11136-015-1196-z","article-title":"Validity, responsiveness, and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing rehabilitation.","volume":"25","author":"Chen","year":"2016","journal-title":"Qual Life Res"},{"issue":"1","key":"doi200056r28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1477-7525-6-46","article-title":"The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease.","volume":"6","author":"Puhan","year":"2008","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"doi200056r31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: What do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"8","key":"doi200056r32","first-page":"1156","article-title":"Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK.","volume":"16","author":"Swinburn","year":"2013","journal-title":"Jval"},{"issue":"3","key":"doi200056r33","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"9993","key":"doi200056r34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate to severe  psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"doi200056r35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate to severe  plaque psoriasis: efficacy and safety results from a phase II randomized controlled study.","volume":"81","author":"Nakagawa","year":"2016","journal-title":"J Dermatol Sci"},{"issue":"6","key":"doi200056r36","doi-asserted-by":"crossref","first-page":"AB178","DOI":"10.1016\/j.jaad.2017.04.691","article-title":"Neuropsychiatric adverse events in brodalumab psoriasis studies.","volume":"76","author":"Lebwohl","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi200056r37","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate to severe  psoriasis: 24-week results from IXORA-S, a phase III study.","volume":"177","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"key":"doi200056r30","author":"Ryan","year":"2018"},{"key":"doi200056r16","unstructured":"Clinicaltrials.gov. BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis. 2017. Accessed October 2018.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02684370"},{"key":"doi200056r17","unstructured":"Clinicaltrials.gov. BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis. 2018. Accessed October 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02684357"},{"key":"doi200056r20","unstructured":"EuroQol Research Foundation. EQ-5D-5L. 2018. Accessed October 2018. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about"},{"key":"doi200056r22","unstructured":"Rentz? A, Mansukhani? S, Esser? D,  Reliability, Validity, and Ability to Detect Change of the Psoriasis Symptom Scale (PSS) in Patients with Plaque Psoriasis. EADV Congress, Paris, France [P2070]. 2018. Accessed October 2018. https:\/\/eadv.m-anage.com\/Login.aspx?event=eadvparis2018"},{"key":"doi200056r29","unstructured":"FDA. Value and Use of Patient-Reported Outcomes (PROs) in Assessing Effects of Medical Devices. 2017. Accessed November 2017. https:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDRH\/CDRHVisionandMission\/UCM588576.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2771625\/jamadermatology_augustin_2020_oi_200056_1607046296.7044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T20:25:10Z","timestamp":1607545510000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2771625"}},"subtitle":["The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.3617","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}